Black Diamond Therapeutics, Inc. (BDTX) Earnings History
Net Loss9 years of earnings data (2017–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Black Diamond Therapeutics, Inc. (BDTX) Earnings Overview
As of June 21, 2026, Black Diamond Therapeutics, Inc. (BDTX) reported trailing twelve-month net income of -$43M, reflecting +130.7% year-over-year growth. The company earned $-0.76 per diluted share over the past four quarters, with a net profit margin of 32.0%.
Looking at the long-term picture, BDTX's historical earnings data spans multiple years. The company achieved its highest annual net income of $22M in fiscal 2025, representing a new all-time high.
Black Diamond Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KYMR (-$315M net income, -794.4% margin), NUVL (-$450M net income), AUPH ($298M net income, 101.5% margin), BDTX has outperformed on profitability metrics. Compare BDTX vs KYMR →
BDTX Earnings vs Peers
Earnings metrics vs comparable public companies
BDTX Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $22M | +132.1% | $20M | $0.39 | 32.0% | 28.4% |
| 2024 | -$70M | +15.5% | -$79M | $-1.27 | - | - |
| 2023 | -$82M | +9.6% | -$86M | $-1.88 | - | - |
| 2022 | -$91M | +27.4% | -$93M | $-2.52 | - | - |
| 2021 | -$126M | -86.7% | -$127M | $-3.47 | - | - |
| 2020 | -$67M | -90.7% | -$70M | $-2.04 | - | - |
| 2019 | -$35M | -294.8% | -$9M | $-1.15 | - | - |
| 2018 | -$9M | -94.1% | -$9M | $-0.64 | - | - |
| 2017 | -$5M | - | -$4M | $-0.64 | - | - |
Download Data
Export BDTX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BDTX — Frequently Asked Questions
Quick answers to the most common questions about buying BDTX stock.
What is BDTX earnings per share (EPS)?
BDTX trailing twelve-month (TTM) diluted EPS is $-0.76, reflecting +130.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2025 is available in the table on this page.
What is Black Diamond Therapeutics, Inc.'s net income?
Black Diamond Therapeutics, Inc. (BDTX) trailing twelve-month net income is $-43M as of 2025. Earnings grew +130.7% year-over-year.
Is BDTX profitable?
BDTX is not currently profitable on a TTM basis, reporting a net loss of $-43M. Net margin is +32.0%. Investors should monitor for a return to profitability.
What is BDTX's earnings growth rate?
BDTX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2025.
What are BDTX's profit margins?
Black Diamond Therapeutics, Inc. net profit margin is +32.0%, operating margin is +28.4%, and gross margin is +99.5%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +22.9%.
Is BDTX growing earnings?
Yes, BDTX earnings are accelerating — EPS growth of +130.7% exceeds the 5-year CAGR of N/A. TTM net income reached $-43M. Earnings momentum is strengthening.
What was BDTX's best earnings year?
Black Diamond Therapeutics, Inc.'s highest annual net income on record is $22M, achieved in fiscal year 2025. Earnings history on this page spans 2017 to 2025 and includes all annual and quarterly figures.
What were BDTX's earnings last quarter?
BDTX's most recent reported quarter was Q1 2026. Net income was $-9M with diluted EPS of $-0.16. For a full breakdown of all quarters, see the quarterly earnings table on this page.